Spyre Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
SYRE$103.86+7.5%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Net loss | $(338,790) | $(83,815) | $(65,801) |
| Other comprehensive income (loss): | |||
| Foreign currency translation adjustment | 37 | (35) | (1) |
| Unrealized gain (loss) on marketable securities | 313 | 7 | (30) |
| Total comprehensive loss | $(338,440) | $(83,843) | $(65,832) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.